Pulmonary arterial hypertension: An update on diagnosis and treatment

American Family Physician

Volumn 82, Issue 4, 2010, Pages 370-377

  Stringham, Richard ^a   Shah, Nipa R ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; DIGOXIN; ILOPROST; INFLUENZA VACCINE; OXYGEN; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; SCL 70 ANTIBODY; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN; ENDOTHELIN RECEPTOR; PHOSPHODIESTERASE V; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ANEMIA; ANTIBODY TITER; ANTICOAGULANT THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARBON DIOXIDE TENSION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEART MURMUR; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; IMMUNIZATION; INFECTION; INJECTION SITE PAIN; INSOMNIA; JAW PAIN; LABORATORY TEST; LIFESTYLE MODIFICATION; LUNG ARTERY PRESSURE; MUSCULOSKELETAL PAIN; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; TRICUSPID VALVE REGURGITATION; VOMITING; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PULMONARY ARTERY; REVIEW;

ANTICOAGULANTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PROSTAGLANDINS I; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; VASODILATOR AGENTS;

EID: 77956399981     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223.
3. Simonneau G, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54.
4. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):40S-47S.
5. Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001;63(9):1789-1798.
6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association [published correction appears in Circulation. 2009;120(2):e13]. Circulation. 2009;119(16):2250-2294.
7. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243-2278.
8. Henkens IR, Gan CT, van Wolferen SA, et al. ECG monitoring of treatment response in pulmonary arterial hypertension patients. Chest. 2008;134(6):1250-1257.
9. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997;36(2):239-243.
10. Ben-Dor I, Kramer MR, Raccah A, et al. Echocardiography versus right-sided heart catheterization among lung transplantation candidates. Ann Thorac Surg. 2006;81(3):1056-1060.
11. Mogollón Jiménez MV, Escoresca Ortega AM, Cabeza Letrán ML, et al. Correlation of echocardiographic and hemodynamic parameters in pulmonary hypertension assessment prior to heart transplantation. Transplant Proc. 2008;40(9):3023-3024.
12. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108-113.
13. Caldas MC, Meira ZA, Barbosa MM. Evaluation of 107 patients with sickle cell anemia through tissue Doppler and myocardial performance index. J Am Soc Echocardiogr. 2008;21(10):1163-1167.
14. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792-3800.
15. Kittipovanonth M, Bellavia D, Chandrasekaran K, Villarraga HR, Abraham TP, Pellikka PA. Doppler myocardial imaging for early detection of right ventricular dysfunction in patients with pulmonary hypertension. J Am Soc Echocardiogr. 2008;21(9):1035-1041.
16. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;52(21):1683-1692.
17. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-3111.
18. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 pt 1):487-492.
19. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112(3):714-721.
20. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81.
21. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788.
22. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
23. Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev. 2005;(2):CD002994.
24. Olschewski H, Simonneau G, Galiè N, et al.; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329.
25. Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Vasc Health Risk Manag. 2008;4(3):507-513.
26. Simonneau G, et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.
27. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep. 2007;56(8):170-172.
28. Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2009;10(11):1847-1858.
29. Hrometz SL, Shields KM. Role of ambrisentan in the management of pulmonary hypertension [published correction appears in Ann Pharmacother. 2009;43(4):794]. Ann Pharmacother. 2008;42(11):1653-1659.
30. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019.
31. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2002;346(16):158]. N Engl J Med. 2002;346(12):896-903.
32. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-1217.
33. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension [published correction appears in Eur Respir J. 2005;25(5):942]. Eur Respir J. 2005;25(2):244-249.
34. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100.
35. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival [published correction appears in Chest. 2009;135(4):1114]. Chest. 2008;134(4):775-782.
36. Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2008;133(1):183-189.
37. Shafiq N, Reddy S, Pandhi P, Manoj R, Talwar KK, Malhotra S. Sildenafil for pulmonary hypertension: need for evidence generation. Int J Clin Pharmacol Ther. 2008;46(12):644-651.
38. Galiè N, Brundage BH, Ghofrani HA, et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-2903.
39. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655-1665.
40. Simonneau G, Rubin LJ, Galiè N, et al.; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial [published corrections appear in Ann Intern Med. 2009;150(1):63, and Ann Intern Med. 2009;151(6):435]. Ann Intern Med. 2008;149(8):521-530.
41. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. Evian, France, September 6-10,1998; cosponsored by the World Health Organization.
42. Ceriana P, Kiersy C, Veronesi R, Braschi A, D'Armini A, Viganò M. Influence of underlying lung disease on early postoperative course after single lung transplantation. Cardiovasc Surg (Torino). 2002;43(5):715-722.
43. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103-1110.
44. Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133-1137.
45. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis. 2002;45(2):115-128.
46. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31(7):1650-1657.
47. Boutet K, Montani D, Jaïs X, et al. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis. 2008;2(4):249-265.